SAN DIEGO and KENNESAW, Ga., Sept. 9, 2013 /PRNewswire/ -- Shareholder rights attorneys at Robbins Arroyo LLP announce that an investor of MiMedx Group, Inc. (NASDAQ: MDXG) has filed a complaint in the U.S. District Court for the Southern District of New York. The complaint alleges that the company and certain of its officers violated the Securities Exchange Act of 1934 from March 15, 2013 to September 4, 2013 (the "Class Period"). MiMedx, together with its subsidiaries, operates as an integrated developer, manufacturer, and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membranes.
MiMedx Accused of Making False and Misleading Statements
According to the complaint, MiMedx issued materially false and misleading statements about whether its AmnioFix Injectable product required U.S. Food and Drug Administration ("FDA") approval to be manufactured and marketed. Specifically, on
March 15, 2013, in its annual report for the fiscal year ended
December 31, 2013, filed with the U.S. Securities and Exchange Commission ("SEC"), MiMedx falsely stated that its products did not require approval from the FDA because of a purported exemption under the Public Health Service Act. The company made similar statements in its quarterly report for the second quarter ended
June 30, 2013, filed with the SEC on
August 8, 2013.
MiMedx Stock Drops on Announcement of Letter from the FDA Asserting Violations of the Public Heath Service Act
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts